April 2nd 2025
The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
View More
Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma
View More
Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies
View More
Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
View More
Endometrial Cancer: Recent Developments in Evaluation and Treatment
December 1st 1999We commend Chen et al for their comprehensive review of the evaluation and treatment of endometrial cancer. As the authors state, endometrial cancer is the most common gynecologic malignancy in the United States. Fortunately, it is also one of the most curable. The majority of women with endometrial cancer are treated by surgery alone; primary radiation therapy is generally reserved for patients with unacceptable risks of surgical morbidity. In this commentary, we will address several areas of current controversy.
Endometrial Cancer: Recent Developments in Evaluation and Treatment
December 1st 1999Endometrial cancer is the fifth leading cause of cancer in women worldwide, with approximately 150,000 cases diagnosed each year, and is the most common malignancy of the female genital tract in the United States. Dr. Chen and colleagues provide an excellent review of current clinical investigations focusing on the evaluation and treatment of this carcinoma.
September Is Gynecologic Cancer Awareness Month
September 1st 1999The Gynecologic Cancer Foundation, along with the American Hospital Association, has declared September 1999 the first annual Gynecologic Cancer Awareness Month. Each year, 82,000 women in the United States (ie, 1 in every 25 women) are
Moderate-Dose External Radiation Plus Implants Increase Survival in Cervical Cancer
July 1st 1999Standard radiation therapy for patients with latestage cervical cancer (stage IIIB) should be adjusted so that each patient receives moderate doses of external-beam radiation therapy plus radioactive implants, according to a study led by Dr. Mark
Church-Based Project Provides Cervical Cancer Screening for Latinas
June 1st 1999SAN FRANCISCO-A single-visit cervical cancer screening program conducted before and after church services may help extend the benefits of early diagnosis and treatment to underserved populations, according to research presented at the 30th annual meeting of the Society of Gynecologic Oncologists.
Commentary (Horowitz): Laparoscopy in Gynecologic Malignancies
June 1st 1999Laparoscopy dates back to 1901 when Kelling inspected a dog’s abdominal cavity with a cystoscope introduced transcutaneously. This technique was subsequently applied to humans in 1923.[1] Jacobaeus, in 1910, developed instruments
Commentary (Spirtos/Eisenkop): Laparoscopy in Gynecologic Malignancies
June 1st 1999Minimally invasive surgery is simply the use of small incisions with specialized equipment to accomplish surgical objectives that would otherwise be completed through larger incisions with conventional equipment. A priority of gyne-cologic oncologists
Chemo Improves Survival in High-Risk Cervical Cancer
June 1st 1999SAN FRANCISCO-A major intergroup phase III study reported at the 30th Annual Meeting of the Society of Gynecologic Oncologists has shown that adding chemotherapy to radiation therapy improves the overall survival rate for women with high-risk early-stage cervical cancer. William A. Peters III, MD, of the Puget Sound Oncology Consortium, Seattle, reported the results on behalf of researchers from the Southwest Oncology Group, Gynecologic Oncology Group, and Radiation Therapy Oncology Group.
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
March 1st 1999The National Cancer Institute (NCI) recently sent a clinical announcement to thousands of physicians stating that strong consideration should be given to adding chemotherapy to radiation therapy in the treatment of invasive cervical cancer.
US Clinical Trial of New Cervical Cancer Detection System to Begin
October 1st 1998NetMed, Inc., a developer and marketer of medical and health-related technologies, announced the commencement of a multicenter US clinical trial of the PAPNET cervical cancer detection system as a primary screening test for Pap smears. The
Practice Guidelines: Uterine Corpus—Endometrial Cancer
January 1st 1998Endometrial cancer is the most common type of female genital cancer in the United States, with an estimated 32,000 new cases and 5,600 deaths per year. During the first half of the 20th century, the incidence of cervical cancer was greater than
Researchers Report Conflicting Data on Cervical Cancer in AIDS
July 1st 1997BETHESDA, Md--A review of 10 years' experience with HIV-infected patients treated at University Hospital, Newark, NJ, revealed significantly elevated levels of several types of cancers, but a surprising dearth of invasive cervical cancers, which prompted the study's lead author to suggest dropping cervical cancer from the list of AIDS-associated malignancies.
Summary of the NIH Consensus Development Conference on Cervical Cancer
May 1st 1997Carcinoma of the cervix is one of the most common malignancies in women, accounting for 15,700 new cases and 4,900 deaths in the United States each year. Worldwide, cervical cancer is second only to breast cancer as the most common
'More May Be Less' in Metastatic Cervical Cancer
February 1st 1997VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.
Breast and Cervical Cancer Early Detection Program to Expand
December 1st 1996WASHINGTON--For the first time since its inception in 1991, funds from the Breast and Cervical Cancer Early Detection Program will flow to all 50 states in fiscal 1997, the Department of Health and Human Services announced.
Benefits of Tamoxifen Outweigh Endometrial Cancer Risk
An expert panel of nine international cancer researchers and practicing oncologists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. The first article in this series, based on the symposium presentations, focused on the optimal duration of tamoxifen use (October 1996). This month, the panel explores the noncancer benefits of tamoxifen, as well as the potential risk of endometrial cancer. The symposium was sponsored by Zeneca Pharmaceuticals.
Changing Concepts in the Management of Endometrial Cancer
July 1st 1996In their comprehensive review of changing concepts in the management of endometrial cancer, Drs. Karasek and Faul highlight the contemporary approach to the management of patients with endometrial adenocarcinoma. The authors stress the evolution
Changing Concepts in the Management of Endometrial Cancer
July 1st 1996The authors present the major issues and controversies surrounding the treatment of endometrial cancer. A variety of therapeutic approaches have been used in the past, including surgery alone, preoperative radiation and surgery, surgery and
DFMO Shows Potential in the Prevention of Cervical Cancer
June 1st 1996NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center, the chemopreventive agent difluorometh-ylornithine (DFMO) produced significant regression of cervical intraepithelial neoplasia (CIN) grade 3, Michele Follen Mitchell, MD, reported at the Society of Gynecologic Oncologists meeting.
Cervical Cancer: Behavioral Changes Could Save Most Women
June 1st 1996Cervical cancer's slow, noticeable growth makes it "an ideal disease" for screening, but poor choices--like not getting a Pap smear or having unprotected sex as young adults--give the disease a disastrous head start, a University of Wisconsin Medical